Ferrara N, Gerber HP, LeCouter J: The biology of VEGF and its rec

Ferrara N, Gerber HP, LeCouter J: The biology of VEGF and its receptors. Nature Medicine 2003, 9:669–676.PubMedCrossRef 24. Piossek C, Schneider-Mergener J, Schirner M, Vakalopoulou E,

Germeroth L, Thierauch KH: Vascular endothelial growth factor (VEGF) receptor II-derived peptides inhibit VEGF. Journal of Biological Chemistry 1999, 274:5612–5619.PubMedCrossRef 25. Arany Z, Foo SY, Ma YH, Ruas JL, Bommi-Reddy A, Girnun G, Cooper M, Laznik D, Chinsomboon J, Rangwala SM, et al.: HIF-independent regulation of VEGF and angiogenesis by the transcriptional coactivator PGC-1 alpha. Nature 2008, 451:1008-U1008.PubMedCrossRef 26. Pan Q, Z-VAD-FMK in vivo Chanthery Y, Liang WC, Stawicki S, Mak J, Rathore N, Tong RK, Kowalski J, Yee SF, Pacheco G, et al.: Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth. Cancer Cell 2007, 11:53–67.PubMedCrossRef 27. Li MY, Lee TW, Mok TSK, Warner TD, Yim APC, Chen GG: Activation of peroxisome proliferator-activated receptor-gamma APR-246 in vivo by troglitazone (TGZ) inhibits human lung cell growth. Journal of Cellular

Biochemistry 2005, 96:760–774.PubMedCrossRef 28. Regina S, Rollin J, Blechet C, Iochmann S, Reverdiau P, Gruel Y: Tissue factor expression in non-small cell lung cancer: Relationship with vascular endothelial growth factor expression, microvascular density, and K-ras mutation. Journal of Thoracic Oncology 2008, 3:689–697.PubMedCrossRef 29. Li M, Hui Y, Chai H, Fisher WE, Wang XP, Brunicardi FC, Yao QZ, Chen CY: Pancreatic carcinoma cells express neuropilins and vascular endothelial growth factor, oxyclozanide but not vascular endothelial growth factor receptors. Cancer 2004, 101:2341–2350.PubMedCrossRef 30. Weidner N, Semple JP, Welch WR, Folkman J: Tumor angiogenesis and metastasis–correlation in invasive breast carcinoma. N Engl J Med 1991, 324:1–8.PubMedCrossRef 31. Weidner N, Carroll PR, Flax J,

Blumenfeld W, Folkman J: Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. American Journal of Pathology 1993, 143:401–409.PubMed 32. Gorski DH, Leal AD, Goydos JS: Differential expression of vascular endothelial growth factor-A isoforms at different stages of melanoma progression. 2003, 408–418. 33. Hicklin DJ, Ellis LM: Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. Journal of Sorafenib research buy Clinical Oncology 2005, 23:1011–1027.PubMedCrossRef 34. Govindarajan R, Ratnasinghe L, Simmons DL, Siegel ER, Midathada MV, Kim L, Kim PJ, Owens RJ, Lang NP: Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes. 2007, 1476–1481. 35. Zhang W, Zhang H, Xing L: Influence of ciglitazone on A549 cells growth in vitro and in vivo and mechanism. J Huazhong Univ Sci Technolog Med Sci 2006, 26:36–39.PubMedCrossRef 36.

Comments are closed.